Evidence map›Paper›PMID 33718795›Full record

ArticleMayo Clinic proceedings. Innovations, quality & outcomes2021

Pulmonary Vascular Disease Due to Plasma Cell Dyscrasia.

Indranee Rajapreyar, Joanna Joly, Jose Tallaj, Salpy V Pamboukian, Ayman Haj Assad, Carrie Lenneman, Silvio Litovsky, Arka Chatterjee, Charles Hoopes, Andrew Lenneman

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Indranee RajapreyarDivision of Cardiovascular Disease, Section of Advanced Heart Failure and Transplantation, University of Alabama at Birmingham, Birmingham.
Joanna JolyDivision of Cardiovascular Disease, Section of Advanced Heart Failure and Transplantation, University of Alabama at Birmingham, Birmingham.
Jose TallajDivision of Cardiovascular Disease, Section of Advanced Heart Failure and Transplantation, University of Alabama at Birmingham, Birmingham.
Salpy V PamboukianDivision of Cardiovascular Disease, Section of Advanced Heart Failure and Transplantation, University of Alabama at Birmingham, Birmingham.
Ayman Haj AssadDivision of Cardiovascular Disease, Section of Advanced Heart Failure and Transplantation, University of Alabama at Birmingham, Birmingham.
Carrie LennemanDivision of Cardiovascular disease, University of Alabama at Birmingham, Birmingham.
Silvio LitovskyDepartment of Pathology, University of Alabama at Birmingham, Birmingham.
Arka ChatterjeeDivision of Cardiovascular disease, University of Alabama at Birmingham, Birmingham.
Charles HoopesDivision of Cardiothoracic Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham.
Andrew LennemanDivision of Cardiovascular Disease, Section of Advanced Heart Failure and Transplantation, University of Alabama at Birmingham, Birmingham.
University of Alabama at Birmingham · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary hypertension (PH) has been described in myeloproliferative disorders; monoclonal plasma cell disorder such as polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome; and plasma cell dyscrasias such as multiple myeloma and amyloidosis. We describe 4 cases of PH likely due to pulmonary vascular involvement and myocardial deposition from light chain deposition disease, amyloidosis, and multiple myeloma. On the basis of our clinical experience and literature review, we propose screening for plasma cell dyscrasia in patients with heart failure with preserved ejection fraction, unexplained PH, and hematological abnormalities. We also recommend inclusion of cardiopulmonary screening in patients with monoclonal gammopathy of undetermined significance.

Indexed as

AL, amyloid light chainASCT, autologous stem cell transplantBMB, bone marrow biopsyCKD, chronic kidney diseaseCT, computed tomographyFLC, free light chainHIV, human immunodeficiency virusILD, interstitial lung diseaseLCDD, light chain deposition diseaseLC-MGUS, light chain monoclonal gammopathy of undetermined significanceLV, left ventricularMGUS, monoclonal gammopathy of undetermined significanceMM, multiple myelomaMRI, magnetic resonance imagingPAP, pulmonary artery pressurePH, pulmonary hypertensionRA, right atrialRHC, right heart catheterizationRV, right ventricle/ventricularTTE, transthoracic echocardiographyWHO, World Health Organization

Identifiers

PMID33718795
PMCPMC7930784
OpenAlexW3108434458

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.